Form 4: Bristol-Myers Squibb Executive Reports Routine RSU Vesting and Share Transactions

A Bristol-Myers Squibb executive, Wendy Short Bartie, reported the vesting of restricted stock units and subsequent share transactions, including tax-related dispositions, on June 3, 2025.

Summary

• Wendy Short Bartie, Executive Vice President of Corporate Affairs at Bristol-Myers Squibb Co (BMY), reported transactions on June 3, 2025.
• She acquired 8,040 shares of common stock through the vesting of restricted stock units (RSUs) at a price of $0.
• Concurrently, 3,334 shares were disposed of at a price of $48.09 per share to cover tax obligations related to the RSU vesting.
• Following these reported transactions, Ms. Bartie directly beneficially owns 4,706 shares of common stock.
• Additionally, 16,080 restricted stock units remain beneficially owned, which are scheduled to vest in two more equal annual installments beginning on June 3, 2026, and concluding on June 3, 2027.

Sentiment

Score: 5

Explanation: Neutral. This is a routine disclosure of executive compensation vesting and tax-related share disposition, which is a normal part of executive compensation and does not indicate positive or negative company performance or outlook.

Positives

• The vesting of restricted stock units indicates the executive is receiving compensation, which aligns their interests with shareholders.
• The acquisition of shares at a $0 price reflects compensation through equity awards, a common component of executive remuneration.

Negatives

• The disposition of 3,334 shares for tax purposes reduces the executive's direct shareholding, though this is a common and expected practice for equity compensation.

Future Outlook

This Form 4 filing is a transactional report and does not provide any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This document is a routine insider transaction report specific to an individual executive's equity compensation and does not provide information relevant to broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The report provides transparency on executive equity compensation, which is a standard practice and aligns executive interests with shareholders. The disposition of shares for taxes is a routine event and does not imply a negative outlook for the company.

Next Steps

• Future vesting of the remaining 16,080 restricted stock units in two additional equal annual installments on June 3, 2026, and June 3, 2027.

Key Dates

Recommendation

Keywords

Bristol-Myers Squibb, BMY, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Executive Compensation, Share Vesting, Tax Withholding, Equity Compensation